Precision medicine has rapidly been applied by oncologists who treat non–small cell lung cancer (NSCLC). In patients with newly diagnosed advanced-stage NSCLC, it is now considered standard of care to offer treatment regimens based on molecular status, but the implications of de novo T790M are not yet widely known. When multiple biopsies show T790M mutations, suspicion of and testing for germline T790M mutations are crucial in providing precise and tailored management for patients with NSCLC and their potentially affected family members.
The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
The preliminary result of this study was accepted for a poster presentation at the 2017 Multidisciplinary Thoracic Cancer Symposium; March 16–18, 2017; San Francisco, California.
Frampton GM, Fichtenholtz A, Otto GA et al.. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023–1031.
Brambilla E, Travis WD. Lung cancer. In: Stewart BW, Wild CP, eds. World Cancer Report 2014. Lyon, France: World Health Organization; 2014.
Travis WD, Brambilla EW, Burke AP et al.. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2015.
Travis WD, Rekhtman N, Riley GJ et al.. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010;5:411–414.
Scagliotti GV, Parikh P, von Pawel J et al.. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–3551.
Johnson DH, Fehrenbacher L, Novotny WF et al.. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–2191.
- Search Google Scholar
- Export Citation
. Johnson DH Fehrenbacher L Novotny WF Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184– 2191.
Mok TS, Wu YL, Thongprasert S et al.. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
Lee CK, Brown C, Gralla RJ et al.. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013;105:595–605.
Goss G, Tsai CM, Shepherd FA et al.. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17:1643–1652.
Yang JC, Ahn MJ, Kim DW et al.. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 2017;35:1288–1296.
Riely G, Yu H, Arcila M et al.. Response to erlotinib and prognosis in patients with de novo epidermal growth factor receptor T790M mutations [abstract]. J Clin Oncol 2013:31(Suppl):Abstract 8018.
Yu HA, Arcila ME, Fleischut MH et al.. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol 2014;9:554–558.
Oxnard GR, Miller VA, Robson ME et al.. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7:1049–1052.
Gazdar A, Robinson L, Oliver D et al.. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 2014;9:456–463.
Yu HA, Arcila ME, Hellmann MD et al.. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014;25:423–428.
National Lung Screening Trial Research Team Aberle DR, Adams AM et al.. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.
de Magalhães JP, Finch CE, Janssens G. Next-generation sequencing in aging research: emerging applications, problems, pitfalls and possible solutions. Ageing Res Rev 2010;9:315–323.
Lindeman NI, Cagle PT, Beasley MB et al.. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828–860.
- Search Google Scholar
- Export Citation
. Lindeman NI Cagle PT Beasley MB Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013; 137: 828– 860.
Ettinger DS, Wood DE, Ainer DL et al.. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, version 6.2017. Accessed May 29, 2017. To view the most recent version of these guidelines, visit NCCN.org.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519–525.
Svaton M, Fiala O, Pesek M et al.. The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third- line chemotherapy. Anticancer Res 2016;36:1077–1082.
Cappuzzo F, Marchetti A, Skokan M et al.. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667–1674.
Johnson BE, Kris MG, Berry LD et al.. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol 2013;31(Suppl):Abstract 8019.